Parkman Healthcare Partners LLC Aurinia Pharmaceuticals Inc. Transaction History

Parkman Healthcare Partners LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$10.93 - $23.55 $546,161 - $1.18 Million	-49,969 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$10.0 - $14.52 $3,880 - $5,633	388 Added 0.78%	49,969 $648,000
Q1 2021 May 14, 2021	SELL	$12.3 - $18.73 $491,040 - $747,739	-39,922 Reduced 44.6%	49,581 $644,000
Q4 2020 Feb 12, 2021	SELL	$12.94 - $16.05 $528,068 - $654,984	-40,809 Reduced 31.32%	89,503 $1.24 Million
Q3 2020 Nov 13, 2020	BUY	$13.19 - $16.66 $316 - $399	24 Added 0.02%	130,312 $1.92 Million
Q2 2020 Aug 13, 2020	BUY	$14.12 - $18.33 $141,200 - $183,299	10,000 Added 8.31%	130,288 $2.12 Million
Q1 2020 May 15, 2020	BUY	$11.34 - $21.46 $230,065 - $435,380	20,288 Added 20.29%	120,288 $1.75 Million
Q4 2019 Feb 13, 2020	BUY	$3.88 - $21.42 $388,000 - $2.14 Million	100,000 New	100,000 $2.03 Million

210

58.1M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.13B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.